Aim: Palbociclib (PAL), ribociclib (RIB) and abemaciclib (ABM), in combination with fulvestrant
(FUL), are approved for the treatment of hormone receptor-positive, HER2-negative
advanced breast cancer. This study aims to determine relative efficacy of ...